Dhanuka Agritech Limited has informed the Exchange about the AGM of the Company to be held on 1st August, 2025 at 11:00 AM
DHANUKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dhanuka Agritech's board approved audited results for Q4 and FY ended March 31, 2025, with revenue from operations growing to Rs. 2,03,515 lacs (up ~16% from Rs. 1,75,854 lacs in FY24). Profit before tax rose to Rs. 39,214 lacs (up ~23% YoY), and consolidated PAT reached Rs. 29,696 lacs (up ~24% YoY), with basic EPS at Rs. 65.55 vs Rs. 52.46. The board recommended a final dividend of Rs. 2 per share (100% on face value of Rs. 2), with a record date of July 18, 2025, and the 40th AGM scheduled for August 1, 2025 via video conferencing. The company completed a Rs. 100 crore buyback in September 2024 and entered agreements with Bayer AG, Germany, to acquire international rights to Iprovalicarb and Triadimenol for expansion into 20+ countries. Independent Director Mr. Siraz Azmat Chaudhary will cease to be a director after completing his first term on July 22, 2025.
Strong double-digit revenue and profit growth, along with a continued 100% dividend, signals healthy operational momentum and shareholder returns. The international expansion via Bayer deal and clean audit opinion are positive for long-term prospects, though near-term stock reaction depends on how this performance compares to street expectations.